EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Therapeutic drug monitoring of imatinib in paediatric chronic myeloid leukaemia: Data from a real‐world setting

Meinolf Suttorp iD, Stephanie Sembill, Phyllis Lensker, Verena Hildebrand, Elke Schirmer, Axel Karow iD, Manuela Krumbholz iD, Manfred Rauh, Markus Metzler

British Journal of Haematology · 2025

DOI: 10.1111/bjh.20047 ↗

Kurz gefasst

Fachartikel in der Zeitschrift British Journal of Haematology, 2025. Verfasst von Meinolf Suttorp und 8 weiteren Autor:innen. Beteiligte Einrichtung: Pediatric Hemato-Oncology, Medical Faculty, Technical University Dresden, Dresden, Germany. Hauptthemen laut MEDLINE: Imatinib Mesylate, Drug Monitoring, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Antineoplastic Agents. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Sonnenstrahl e.V. Dresden-Förderkreis für krebskranke Kinder und Jugendliche, Verein Kaminkehrer helfen krebskranken Kindern, IZKF-Erlangen.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Imatinib (IMA) therapy for paediatric chronic myeloid leukemia (pCML) requires age‐dependent dose adjustments. Assessment of therapeutic drug monitoring (TDM) under ‘real‐world’ conditions was performed. Collection of blood and TDM‐relevant data, calculation of individual dosage exposure, measurement of plasma C min (IMA, Nor‐IMA) by HPLC/MS‐MS and recording of adverse event (AE). Two hundred and forty‐six specimens from 66 patients were analysed. Individual median IMA dosage exposure was 253 mg/m 2 (range: 128–504). Children 1000 ng/mL with achieving OMR demonstrated in each 63% ( N = 24/37, N = 27/43, respectively) patients at months 3 and 6. In the cohort with lower levels, only 23% and 50%, respectively, achieved these milestones. This difference was significant only at month 3. Of 66 patients, 30 reported 125 AEs with gastrointestinal and musculoskeletal as leading complaints. In 9.3% of AEs, the correlated IMA C min was ≥3000 ng/mL. TDM is a simple and rapid additional tool for managing pCML under ‘real‐world conditions’.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Imatinib MesylateDrug MonitoringLeukemia, Myelogenous, Chronic, BCR-ABL PositiveAntineoplastic AgentsHumansChildAdolescentMaleFemaleChild, PreschoolInfant

Stichwörter der Autor:innen

CMLimatinibpaediatric oncologypharmacokinetics

Substanzen

Imatinib MesylateAntineoplastic Agents

Autor:innen und Institutionen

  • Pediatric Hemato-Oncology, Medical Faculty, Technical University Dresden, Dresden, Germany.
  • Pediatric Oncology and Hematology, Department of Pediatrics and Adolescent Medicine, University Hospital Erlangen, Erlangen, Germany.
  • Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), Erlangen, Germany.
  • Bavarian Cancer Research Center (BZKF), Erlangen, Germany.
  • Pharmacy Department, University Hospital Erlangen and Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany.
  • Institute of Experimental and Clinical Pharmacology and Toxicology, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany.

ORCID-Profile: Meinolf Suttorp, Axel Karow, Manuela Krumbholz

Förderung

  • Sonnenstrahl e.V. Dresden-Förderkreis für krebskranke Kinder und Jugendliche
  • Verein Kaminkehrer helfen krebskranken Kindern
  • IZKF-Erlangen
  • Sächsische Landes- und Universitätsbibliothek (SLUB)
  • Sächsische Landesbibliothek – Staats- und Universitätsbibliothek Dresden

Zitieren

APA

Suttorp, M., Sembill, S., Lensker, P., Hildebrand, V., Schirmer, E., Karow, A., Krumbholz, M., Rauh, M., & Metzler, M. (2025). Therapeutic drug monitoring of imatinib in paediatric chronic myeloid leukaemia: Data from a real‐world setting. British Journal of Haematology. https://doi.org/10.1111/bjh.20047

Vancouver

Suttorp M, Sembill S, Lensker P, Hildebrand V, Schirmer E, Karow A, et al. Therapeutic drug monitoring of imatinib in paediatric chronic myeloid leukaemia: Data from a real‐world setting. British Journal of Haematology. 2025. doi:10.1111/bjh.20047

BibTeX
@article{Suttorp2025,
  author = {Suttorp, Meinolf and Sembill, Stephanie and Lensker, Phyllis and Hildebrand, Verena and Schirmer, Elke and Karow, Axel and Krumbholz, Manuela and Rauh, Manfred and Metzler, Markus},
  title = {Therapeutic drug monitoring of imatinib in paediatric chronic myeloid leukaemia: Data from a real‐world setting},
  journal = {British Journal of Haematology},
  year = {2025},
  doi = {10.1111/bjh.20047}
}
Kostenlos starten →